Cargando…

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients

Homologous recombination deficiency (HRD) testing has been approved by FDA for selecting epithelial ovarian cancer (EOC) patients who may benefit from the first-line poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy. However, the effects of HRD on the clinical outcomes of first-line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lei, Gu, Yu, Zhang, Mengpei, Shi, Xiaohua, Li, Zhe, Xu, Xinyun, Sun, Tianqi, Dong, Yu, Xue, Chao, Zhu, Xiaoru, Lv, Ran, Jiao, Kai, Ji, Xuwo, Wang, Li-juan, Zhang, Yang, Liang, Zhiyong, Jin, Ying, Yin, Rutie, Wu, Ming, Liang, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232447/ https://www.ncbi.nlm.nih.gov/pubmed/37258600 http://dx.doi.org/10.1038/s41698-023-00402-y

Ejemplares similares

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6
por: Kemin, Li, et al.
Publicado: (2022)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials
por: Kemin, Li, et al.
Publicado: (2023)

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study
por: Li, Kemin, et al.
Publicado: (2022)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

Implementing HRD technology /
Publicado: (1999)

Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3
por: Schoebel, Stefan, et al.
Publicado: (2017)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro
por: Guru, Navjot, et al.
Publicado: (2021)

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers
por: Tao, Hao‐Yun, et al.
Publicado: (2022)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

Endoplasmic Reticulum Degradation Requires Lumen to Cytosol Signaling: Transmembrane Control of Hrd1p by Hrd3p
por: Gardner, Richard G., et al.
Publicado: (2000)

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
por: Galland, Loïck, et al.
Publicado: (2022)

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
por: Stemmer, Amos, et al.
Publicado: (2020)

The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC)
por: Rose, Peter G, et al.
Publicado: (2021)

Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer
por: Yang, Dong, et al.
Publicado: (2023)

A Hrd way for MHC-II expression
por: Melo-Cardenas, Johanna, et al.
Publicado: (2015)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
por: Sun, Chenggong, et al.
Publicado: (2020)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
por: Di Raimo, Tania, et al.
Publicado: (2020)

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
por: O’Sullivan, Julia, et al.
Publicado: (2023)

HRD1 prevents apoptosis in renal tubular epithelial cells by mediating eIF2α ubiquitylation and degradation
por: Huang, Yujie, et al.
Publicado: (2017)

HRD1 sensitizes breast cancer cells to Tamoxifen by promoting S100A8 degradation
por: Wang, YanYang, et al.
Publicado: (2017)

Proteomic characterization of endogenous substrates of mammalian ubiquitin ligase Hrd1
por: Ye, Yilin, et al.
Publicado: (2018)

Putative Interaction Proteins of the Ubiquitin Ligase Hrd1 in Magnaporthe oryzae
por: Jiang, Haolang, et al.
Publicado: (2018)

HRD1 suppresses the growth and metastasis of breast cancer cells by promoting IGF-1R degradation
por: Xu, Yue-Mei, et al.
Publicado: (2015)

Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: A case report
por: Mu, Xiyan, et al.
Publicado: (2018)

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway
por: Cao, Qi, et al.
Publicado: (2023)

Low E2F2 activity is associated with high genomic instability and PARPi resistance
por: Rennhack, Jonathan P., et al.
Publicado: (2020)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity
por: Xu, Yuanming, et al.
Publicado: (2016)

The role of Hrd1 in ultraviolet (UV) radiation induced photoaging
por: Jin, Yi, et al.
Publicado: (2020)

Increased HRD score in cisplatin resistant penile cancer cells
por: Winkelmann, Ria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_loie5t53eaicheivo8qhj60d39